Ziccum AB (publ) (ZICC.ST)
SEK 0.25
(0.0%)
SEK 0.25
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.97 Million SEK | -55.02% |
| 2022 | 33.28 Million SEK | -9.8% |
| 2021 | 36.9 Million SEK | -6.91% |
| 2020 | 39.64 Million SEK | 115.49% |
| 2019 | 18.39 Million SEK | 43.88% |
| 2018 | 12.78 Million SEK | 636.04% |
| 2017 | 1.73 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 20.3 Million SEK | 35.63% |
| 2024 Q3 | 9.84 Million SEK | -37.64% |
| 2024 Q2 | 15.79 Million SEK | -22.24% |
| 2023 FY | 14.97 Million SEK | -55.02% |
| 2023 Q1 | 28.91 Million SEK | -13.13% |
| 2023 Q3 | 21.76 Million SEK | -11.65% |
| 2023 Q2 | 24.63 Million SEK | -14.8% |
| 2023 Q4 | 14.97 Million SEK | -31.21% |
| 2022 Q4 | 33.28 Million SEK | -21.83% |
| 2022 Q2 | 51.1 Million SEK | -12.34% |
| 2022 FY | 33.28 Million SEK | -9.8% |
| 2022 Q1 | 58.29 Million SEK | 57.98% |
| 2022 Q3 | 42.58 Million SEK | -16.67% |
| 2021 Q2 | 33.64 Million SEK | -5.79% |
| 2021 FY | 36.9 Million SEK | -6.91% |
| 2021 Q3 | 29.34 Million SEK | -12.78% |
| 2021 Q1 | 35.71 Million SEK | -9.9% |
| 2021 Q4 | 36.9 Million SEK | 25.73% |
| 2020 Q3 | 42.72 Million SEK | -13.27% |
| 2020 Q2 | 49.25 Million SEK | 245.17% |
| 2020 Q1 | 14.27 Million SEK | -22.42% |
| 2020 FY | 39.64 Million SEK | 115.49% |
| 2020 Q4 | 39.64 Million SEK | -7.21% |
| 2019 Q4 | 18.39 Million SEK | 153.76% |
| 2019 Q3 | 7.24 Million SEK | -19.63% |
| 2019 Q2 | 9.02 Million SEK | -18.75% |
| 2019 FY | 18.39 Million SEK | 43.88% |
| 2019 Q1 | 11.1 Million SEK | -13.17% |
| 2018 FY | 12.78 Million SEK | 636.04% |
| 2018 Q4 | 12.78 Million SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q2 | 3.63 Million SEK | 0.0% |
| 2017 Q4 | 1.73 Million SEK | 0.0% |
| 2017 FY | 1.73 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | 87.846% |
| Amniotics AB (publ) | 26.08 Million SEK | 42.605% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -146.372% |
| BioArctic AB (publ) | 1.18 Billion SEK | 98.738% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.212% |
| Saniona AB (publ) | 64.14 Million SEK | 76.658% |
| Simris Alg AB (publ) | 174.55 Million SEK | 91.423% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 96.983% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -0.693% |
| NextCell Pharma AB | 81.28 Million SEK | 81.582% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 50.38% |
| AcouSort AB (publ) | 34.51 Million SEK | 56.619% |
| Active Biotech AB (publ) | 44 Million SEK | 65.973% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 87.36% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.215% |
| Cantargia AB (publ) | 223.71 Million SEK | 93.307% |
| Genovis AB (publ.) | 288.85 Million SEK | 94.817% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 82.433% |
| Mendus AB (publ) | 755.95 Million SEK | 98.019% |
| Kancera AB (publ) | 65.64 Million SEK | 77.192% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 98.81% |
| LIDDS AB (publ) | 17.65 Million SEK | 15.197% |
| Lipum AB (publ) | 12.11 Million SEK | -23.633% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 55.443% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 94.629% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 25.293% |
| OncoZenge AB (publ) | 20.34 Million SEK | 26.391% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 97.709% |
| Xintela AB (publ) | 18.39 Million SEK | 18.608% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 89.351% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 98.044% |
| CombiGene AB (publ) | 120.61 Million SEK | 87.587% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 93.102% |
| Intervacc AB (publ) | 259.61 Million SEK | 94.233% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 75.998% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 64.318% |
| Corline Biomedical AB | 100.1 Million SEK | 85.044% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 91.547% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 75.911% |
| Aptahem AB (publ) | 63.02 Million SEK | 76.244% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 95.739% |
| Fluicell AB (publ) | 9.34 Million SEK | -60.3% |
| Biovica International AB (publ) | 131.4 Million SEK | 88.606% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 71.743% |
| Abliva AB (publ) | 87.49 Million SEK | 82.889% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 98.031% |
| 2cureX AB (publ) | 16.62 Million SEK | 9.943% |
| I-Tech AB | 152.44 Million SEK | 90.179% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 98.529% |
| Cyxone AB (publ) | 43.65 Million SEK | 65.704% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 80.974% |
| Biosergen AB | 7.2 Million SEK | -107.916% |
| Nanologica AB (publ) | 77.42 Million SEK | 80.664% |
| SynAct Pharma AB | 228.01 Million SEK | 93.434% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 44.057% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.931% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 31.014% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 93.719% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -77.079% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 82.805% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 47.481% |